BRAF inhibitors such as vemurafenib have been shown to be more effective in metastatic melanomas with BRAFV600E mutation rather than CRCs because epidermal growth factor receptor (EGFR) on the surface of CRC cells can reactivate RAS and CRAF-mediated MAPK signaling pathway in the state of BRAF inhibition [23]. The gene discussed is BRAF; the disease is metastatic melanoma.